JP2023507740A5 - - Google Patents

Info

Publication number
JP2023507740A5
JP2023507740A5 JP2022537008A JP2022537008A JP2023507740A5 JP 2023507740 A5 JP2023507740 A5 JP 2023507740A5 JP 2022537008 A JP2022537008 A JP 2022537008A JP 2022537008 A JP2022537008 A JP 2022537008A JP 2023507740 A5 JP2023507740 A5 JP 2023507740A5
Authority
JP
Japan
Prior art keywords
seq
sequence
lcdr1
lcdr2
hcdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507740A (ja
JP7600240B2 (ja
Filing date
Publication date
Priority claimed from GBGB1919019.8A external-priority patent/GB201919019D0/en
Application filed filed Critical
Publication of JP2023507740A publication Critical patent/JP2023507740A/ja
Publication of JP2023507740A5 publication Critical patent/JP2023507740A5/ja
Priority to JP2024200599A priority Critical patent/JP2025015730A/ja
Application granted granted Critical
Publication of JP7600240B2 publication Critical patent/JP7600240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537008A 2019-12-20 2020-12-18 Ｐｓｍａに結合する抗原結合ドメイン Active JP7600240B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024200599A JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1919019.8 2019-12-20
GBGB1919019.8A GB201919019D0 (en) 2019-12-20 2019-12-20 Antigen-binding domain
PCT/GB2020/053289 WO2021123810A1 (en) 2019-12-20 2020-12-18 Antigen-binding domain binding to psma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024200599A Division JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Publications (3)

Publication Number Publication Date
JP2023507740A JP2023507740A (ja) 2023-02-27
JP2023507740A5 true JP2023507740A5 (https=) 2023-10-26
JP7600240B2 JP7600240B2 (ja) 2024-12-16

Family

ID=69322734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537008A Active JP7600240B2 (ja) 2019-12-20 2020-12-18 Ｐｓｍａに結合する抗原結合ドメイン
JP2024200599A Pending JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024200599A Pending JP2025015730A (ja) 2019-12-20 2024-11-18 Ｐｓｍａに結合する抗原結合ドメイン

Country Status (8)

Country Link
US (1) US12496314B2 (https=)
EP (1) EP4076509A1 (https=)
JP (2) JP7600240B2 (https=)
CN (1) CN114828879A (https=)
AU (1) AU2020406862A1 (https=)
CA (1) CA3161844A1 (https=)
GB (1) GB201919019D0 (https=)
WO (1) WO2021123810A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
KR20250133776A (ko) 2023-02-10 2025-09-08 아뮤닉스 파마슈티컬스, 인크. 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
JPWO2016111344A1 (ja) * 2015-01-08 2017-10-26 協和発酵キリン株式会社 Ｔｒａｉｌｒ２とｐｓｍａに結合するバイスペシフィック抗体
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
BR112018070948A2 (pt) * 2016-04-13 2019-01-29 Orimabs Ltd. anticorpos anti-psma e utilização dos mesmos
GB201607968D0 (en) * 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
MX2020009272A (es) * 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
TWI908706B (zh) * 2018-03-07 2025-12-21 美商波西達治療公司 ＣＡＲＴｙｒｉｎ組成物和使用方法
CN108640999B (zh) 2018-03-27 2021-08-13 广东万海细胞生物科技有限公司 一种靶向表达psma表面抗原的细胞的嵌合抗原受体
CN110526984A (zh) 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN110526976A (zh) 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 一种靶向psma的单链抗体、嵌合抗原受体t细胞及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP2022512132A (ja) 抗クローディン抗体及びそれらの使用
JP2024109678A5 (https=)
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2022058345A5 (https=)
JP2021514664A5 (https=)
SA521422116B1 (ar) أجسام مضادة لـ pd-1 جديدة
CN114502591A (zh) 靶向bcma的抗体、双特异性抗体及其用途
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
JP2020522281A5 (https=)
JP2020522280A5 (https=)
CN107151269A (zh) 一种pdl‑1抗体、其药物组合物及其用途
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2022507485A (ja) Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用
JP2023540526A5 (https=)
JP2023507740A5 (https=)
WO2016005950A1 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
US20250179195A1 (en) Anti-flt3 antibodies and compositions
JP2020533965A5 (https=)
JP2021517459A5 (https=)
JP2021512652A5 (https=)
US20220315982A1 (en) Methods for identification of antigen binding specificity of antibodies
JP2023509373A5 (https=)
JP2020531003A5 (https=)
JP2024522075A5 (https=)
JP2019509714A5 (https=)